David Hallal - Jun 8, 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Director
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Jun 8, 2022
Transactions value $
-$487,173
Form type
4
Date filed
6/10/2022, 07:51 PM
Previous filing
Jun 6, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITOS Common Stock Options Exercise $25.2K +5.97K $4.23 5.97K Jun 8, 2022 Direct
transaction ITOS Common Stock Sale -$122K -5.97K -100% $20.39 0 Jun 8, 2022 Direct F1
transaction ITOS Common Stock Options Exercise $35.1K +11.9K $2.95* 11.9K Jun 8, 2022 Direct
transaction ITOS Common Stock Sale -$243K -11.9K -100% $20.39 0 Jun 8, 2022 Direct F1
transaction ITOS Common Stock Options Exercise $44.7K +10.6K $4.23 10.6K Jun 8, 2022 Direct
transaction ITOS Common Stock Sale -$210K -10.6K -100% $19.86 0 Jun 8, 2022 Direct F2
transaction ITOS Common Stock Options Exercise $4.95K +1.17K $4.23 1.17K Jun 9, 2022 Direct
transaction ITOS Common Stock Sale -$22.8K -1.17K -100% $19.51 0 Jun 9, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -5.97K -3.64% $0.00 158K Jun 8, 2022 Common Stock 5.97K $4.23 Direct F4
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -11.9K -32.13% $0.00 25.1K Jun 8, 2022 Common Stock 11.9K $2.95 Direct F4
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -10.6K -6.7% $0.00 147K Jun 8, 2022 Common Stock 10.6K $4.23 Direct F4
transaction ITOS Stock Option (Right to Buy) Options Exercise $0 -1.17K -0.79% $0.00 146K Jun 9, 2022 Common Stock 1.17K $4.23 Direct F4
transaction ITOS Stock Option (Right to Buy) Award $0 +17.5K $0.00 17.5K Jun 9, 2022 Common Stock 17.5K $18.78 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.1 to $20.84, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.75 to $20.12, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.37 to $19.62, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 One-fourth of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis following the one-year anniversary of the vesting commencement date, subject to the reporting person continuous service relationship with the Issuer through each applicable vesting date.
F5 This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.